27 May 2021

To: Recipients of EP37, 1st ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Combined Corrections

This notice is intended to inform users of corrections made to CLSI document EP37, Supplemental Tables for Interference Testing in Clinical Chemistry, 1st ed. The corrections are described below and shown as highlighted and/or stricken text in the table excerpts.

Correction: 27 May 2021

Table 1. Testing Concentrations for Exogenous Interferents:

The simvastatin concentrations were listed incorrectly as:

- Highest drug concentration under therapeutic treatment: 5.60E−02 mg/dL
- Highest drug concentration under therapeutic treatment: 1.34E+00 µmol/L
- Recommended test concentration: 1.68E−01 mg/dL
- Recommended test concentration: 4.01E+00 µmol/L

The simvastatin concentrations have been corrected to read:

- Highest drug concentration under therapeutic treatment: 2.77E−03 mg/dL
- Highest drug concentration under therapeutic treatment: 6.62E−02 µmol/L
- Recommended test concentration: 8.31E−03 mg/dL
- Recommended test concentration: 1.99E−01 µmol/L

Table 1. Testing Concentrations for Exogenous Interferents

<table>
<thead>
<tr>
<th>Exogenous Potential Interferent (Drug INN)</th>
<th>Highest Drug Concentration Under Therapeutic Treatment, mg/dL</th>
<th>Conversion Factor</th>
<th>Highest Drug Concentration Under Therapeutic Treatment, µmol/L</th>
<th>Recommended Test Concentration, mg/dL</th>
<th>Recommended Test Concentration, µmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin</td>
<td>5.60E−02, 2.77E−03</td>
<td></td>
<td>1.34E+00, 6.62E−02</td>
<td>1.68E−01, 8.31E−03</td>
<td>4.01E+00, 1.99E−01</td>
</tr>
</tbody>
</table>
Correction: 17 September 2019

Table 1. Testing Concentrations for Exogenous Interferents:

The dabigatran concentrations were listed incorrectly as:

- Highest drug concentration under therapeutic treatment: 1.75E+01 mg/dL
- Highest drug concentration under therapeutic treatment: 3.71E+02 µmol/L
- Recommended test concentration: 5.25E+01 mg/dL
- Recommended test concentration: 1.11E+03 µmol/L

The dabigatran concentrations have been corrected to read:

- Highest drug concentration under therapeutic treatment: 3.00E−01 mg/dL
- Highest drug concentration under therapeutic treatment: 6.37E+00 µmol/L
- Recommended test concentration: 9.00E−01 mg/dL
- Recommended test concentration: 1.91E+01 µmol/L

<table>
<thead>
<tr>
<th>Exogenous Potential Interferent (Drug INN)</th>
<th>Highest Drug Concentration Under Therapeutic Treatment, mg/dL</th>
<th>Conversion Factor</th>
<th>Highest Drug Concentration Under Therapeutic Treatment, µmol/L</th>
<th>Recommended Test Concentration, mg/dL</th>
<th>Recommended Test Concentration, µmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran</td>
<td>1.75E+01</td>
<td></td>
<td>3.71E+02</td>
<td>5.25E+01</td>
<td>1.11E+03</td>
</tr>
<tr>
<td></td>
<td>3.00E−01</td>
<td></td>
<td>6.37E+00</td>
<td>9.00E−01</td>
<td>1.91E+01</td>
</tr>
</tbody>
</table>

Correction: 25 July 2018

Table 2. Testing Concentrations for Endogenous Interferents:

In the first paragraph of the introductory information for Table 2, Table 1 is incorrectly listed. The text has been corrected to read, “In Table 12, the test concentration is the endogenous concentration plus the added amount.”

In the table, the recommended test concentration for conjugated bilirubin is listed incorrectly as “684 µmol/L.” The recommended test concentration was corrected to read “475 µmol/L.”

<table>
<thead>
<tr>
<th>Endogenous Potential Interferent</th>
<th>Conventional Units and SI-Derived Units</th>
<th>Conversion to SI Conversion Factor</th>
<th>Recommended Test Concentration*</th>
<th>Endogenous Interferent Reference Interval1, except when indicated otherwise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilirubin, conjugated</td>
<td>mg/dL</td>
<td>11.86</td>
<td>40</td>
<td>0.0–0.2</td>
</tr>
<tr>
<td></td>
<td>µmol/L</td>
<td></td>
<td>684</td>
<td>475</td>
</tr>
</tbody>
</table>

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.